Connect with us

Health

High TMB Gastric Cancer Patients Benefit From ICI Therapy.

Published

on

High TMB Gastric Cancer Patients Benefit From ICI Therapy.

(CTN News) – A recent meta-analysis published in International Immunopharmacology has revealed that patients diagnosed with gastric cancer may experience better outcomes from immune checkpoint inhibitor (ICI) treatment if they possess a high tumor mutational burden (TMB).

The study found that patients with a high TMB had longer overall survival (OS) and progression-free survival (PFS), with Asian patients driving the benefits.

The meta-analysis included 11 retrospective studies of patients with Gastric Cancer or gastroesophageal Gastric Cancer who were treated with ICIs, with 9 studies conducted in Asian countries and 2 in non-Asian countries.

In 6 studies, patients were administered combination treatment, while in 5 studies, they received ICI monotherapy. The ICIs used in these studies were nivolumab, pembrolizumab, atezolizumab, tislelizumab, and toripalimab.

Based on data from 8 studies, the researchers discovered that patients with a high TMB had a significantly longer overall survival (OS) compared to those with a low TMB.

The hazard ratio (HR) was 0.65 with a 95% confidence interval (CI) of 0.55-0.77, and the p-value was less than 0.001.

Using data from 10 studies, the researchers also found that patients with a high TMB had a significantly longer progression-free survival (PFS) compared to those with a low TMB. The HR was 0.51 with a 95% CI of 0.33-0.77, and the p-value was 0.001.

Upon conducting a subgroup analysis, it was observed that the OS benefit was significant in Asian patients with a high TMB. The HR was 0.56 with a 95% CI of 0.43-0.72, and the p-value was less than 0.001. However, this benefit was not observed in non-Asian patients with a high TMB. The HR was 0.61 with a 95% CI of 0.32-1.16, and the p-value was 0.133.

In Asian patients with a high TMB, the PFS benefit was found to be Gastric Cancer significant (HR, 0.45; 95% CI, 0.28-0.72; P =.001). However, this benefit was not observed in non-Asian patients with a high TMB (HR, 0.68; 95% CI, 0.31-1.48; P =.322).

Interestingly, the OS in high-TMB patients remained similar regardless of whether they received combination therapy or monotherapy. On the other hand, the PFS benefit was significant in high-TMB patients who received monotherapy (HR, 0.39; 95% CI, 0.22-0.67; P =.001), but not in those who received combination therapy (HR, 0.84; 95% CI, 0.65-1.08; P =.192).

The researchers of this meta-analysis concluded that gastric cancer patients with high TMB, especially in Asian populations, experienced significant benefits from ICIs compared to those with low TMB. They also emphasized the need for a large number of randomized clinical trials (RCTs) to further establish TMB as a reliable predictor for the prognosis of gastric cancer patients treated with ICIs.

SEE ALSO:

The Resurgence of Alzheimer’s Vaccines in Light of Recent Drug Success

 

Continue Reading

CTN News App

CTN News App

české casino

Recent News

BUY FC 24 COINS

compras monedas fc 24

Volunteering at Soi Dog

Find a Job

Jooble jobs

Free ibomma Movies